As of 17 October 2025, the valuation grade for Protalix Biotherapeutics, Inc. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be overvalued based on its current metrics, with a P/E ratio of 32, significantly higher than its peer Puma Biotechnology, Inc., which has a P/E of 4.74, and a notable EV to EBITDA ratio of 15.52 compared to Puma's 3.15. Additionally, Protalix's Price to Book Value stands at 2.78, suggesting a premium over its book value relative to peers.
In terms of performance, Protalix has shown strong returns over the past year, with a stock return of 70.64%, outpacing the S&P 500's return of 14.08%. However, the longer-term outlook is less favorable, as the stock has underperformed the S&P 500 over the 5-year and 10-year periods, with returns of -48.90% compared to 91.29% for the index. This mixed performance, combined with high valuation ratios, reinforces the conclusion that Protalix Biotherapeutics, Inc. is currently overvalued.